Description

BDTX-1535 is an orally bioavailable, brain-penetrating, mutation-selective, EGFR inhibitor with potential antitumor activity.

BDTX-1535 is a fourth-generation EGFR inhibitor that overcomes resistance to Osimertinib, the standard of care for EGFR-mutant non–small cell lung cancer (NSCLC). BDTX-1535 works well in NSCLC carrying C797S.

Importantly, BDTX-1535 can cross the blood-brain barrier and potentially treat CNS metastases in NSCLC. BDTX-1535 is also highly potent in EGFR-mutant glioblastoma cell lines and mouse models.

Technical Data

Product Name: BDTX-1535

Chemical Formula: C30H30ClFN6O2

Molecular Weight: 561.06

CAS#: 2607829-38-7

Appearance: Solid powder

Purity: > 99% by HPLC

Solubility: Soluble in DMSO

Storage: Room temperature for months, or -20ºC for 3 years.

Targets: EGFR
Synonym: BDTX-1535; BDTX1535; BDTX 1535
Chemical Name/IUPAC:(2E)-N-[4-[(3-Chloro-2-fluorophenyl)amino]-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hex-1-yl]ethynyl]-6-quinazolinyl]-4-(4-morpholinyl)-2-butenamide
SMILES Code: O=C(NC1=CC2=C(NC3=CC=CC(Cl)=C3F)N=CN=C2C=C1C#C[C@]45CN(C)C[C@@]4([H])C5)/C=C/CN6CCOCC6

Disclaimer: For laboratory research use only.